

Takaaki Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1597750/publications.pdf>

Version: 2024-02-01

77
papers

1,649
citations

279798

23
h-index

361022

35
g-index

77
all docs

77
docs citations

77
times ranked

2163
citing authors

#	ARTICLE	IF	CITATIONS
1	Outbreak of <i>Pneumocystis jirovecii</i> Pneumonia in Renal Transplant Recipients: <i>P. jirovecii</i> Is Contagious to the Susceptible Host. <i>Transplantation</i> , 2009, 88, 380-385.	1.0	101
2	Are N-glycolylneuraminic acid (Hanganutziu-Deicher) antigens important in pig-to-human xenotransplantation?. <i>Xenotransplantation</i> , 2004, 11, 247-253.	2.8	98
3	De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury. <i>Transplantation</i> , 2016, 100, 2194-2202.	1.0	74
4	Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. <i>Xenotransplantation</i> , 2010, 17, 26-37.	2.8	65
5	Comparative Study on Signal Transduction in Endothelial Cells After Anti-A/B and Human Leukocyte Antigen Antibody Reaction. <i>Transplantation</i> , 2012, 93, 390-397.	1.0	57
6	Regulation of Clinical Xenotransplantation—Time for a Reappraisal. <i>Transplantation</i> , 2017, 101, 1766-1769.	1.0	57
7	Herpes Zoster-Attributable Resource Utilization and Cost Burden in Patients With Solid Organ Transplant. <i>Transplantation</i> , 2014, 97, 1178-1184.	1.0	52
8	Molecular Cloning of Endo- β -galactosidase C and Its Application in Removing β -Galactosyl Xenoantigen from Blood Vessels in the Pig Kidney. <i>Journal of Biological Chemistry</i> , 2000, 275, 19368-19374.	3.4	51
9	Anti-Gal, β -Gal Epitopes, and Xenotransplantation. , 1999, 32, 229-257.		48
10	Clinical Significance of Regulatory T-Cell-Related Gene Expression in Peripheral Blood After Renal Transplantation. <i>Transplantation</i> , 2011, 91, 191-198.	1.0	40
11	Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. <i>Kidney International</i> , 2014, 85, 425-430.	5.2	40
12	Association of Dialysis Duration with Outcomes after Transplantation in a Japanese Cohort. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 497-504.	4.5	38
13	Influence of olive-derived hydroxytyrosol on the toll-like receptor 4-dependent inflammatory response of mouse peritoneal macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 1225-1230.	2.1	36
14	Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1210-1215.	2.1	32
15	Kidney Volume Changes in Patients With Autosomal Dominant Polycystic Kidney Disease After Renal Transplantation. <i>Transplantation</i> , 2012, 93, 794-798.	1.0	32
16	Current status of pig kidney xenotransplantation. <i>International Journal of Surgery</i> , 2015, 23, 229-233.	2.7	31
17	A Retrospective Study of the Impact of Intraoperative Intact Parathyroid Hormone Monitoring During Total Parathyroidectomy for Secondary Hyperparathyroidism. <i>Medicine (United States)</i> , 2015, 94, e1213.	1.0	30
18	Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. <i>Human Immunology</i> , 2011, 72, 11-17.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Removal of blood group A/B antigen in organs by ex vivo and in vivo administration of endo- α -galactosidase (ABase) for ABO-incompatible transplantation. <i>Transplant Immunology</i> , 2009, 20, 132-138.	1.2	28
20	Production of cloned pigs expressing human thrombomodulin in endothelial cells. <i>Xenotransplantation</i> , 2012, 19, 82-91.	2.8	28
21	Comparative study of efficacy of removal of anti-ABO and anti-gal antibodies by double filtration plasmapheresis. <i>Xenotransplantation</i> , 2000, 7, 101-108.	2.8	26
22	Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment. <i>Clinical Transplantation</i> , 2017, 31, e13071.	1.6	26
23	Analysis of T and B Cell Epitopes to Predict the Risk of de novo Donor-Specific Antibody (DSA) Production After Kidney Transplantation: A Two-Center Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2020, 11, 2000.	4.8	26
24	Role of AMP-Activated Protein Kinase in Ferritin H Gene Expression by Resveratrol in Human T Cells. <i>Biochemistry</i> , 2013, 52, 5075-5083.	2.5	24
25	First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Chapter 1: update on national regulatory frameworks pertinent to clinical is. <i>Xenotransplantation</i> , 2016, 23, 14-24.	2.8	24
26	MiR-142-5p and miR-486-5p as biomarkers for early detection of chronic antibody-mediated rejection in kidney transplantation. <i>Biomarkers</i> , 2017, 22, 45-54.	1.9	24
27	Successful crossbreeding of cloned pigs expressing endo- α -galactosidase C and human decay accelerating factor. <i>Xenotransplantation</i> , 2009, 16, 511-521.	2.8	23
28	α -Galactosyl Oligosaccharides Conjugated with Polyethylene Glycol as Potential Inhibitors of Hyperacute Rejection upon Xenotransplantation. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 731-736.	2.1	21
29	Adipose-derived stromal cells cultured in a low-serum medium, but not bone marrow-derived stromal cells, impede xenoantibody production. <i>Xenotransplantation</i> , 2011, 18, 196-208.	2.8	21
30	A proliferation-inducing ligand sustains the proliferation of human naive (CD27 ⁺) B cells and mediates their differentiation into long-lived plasma cells in vitro via transmembrane activator and calcium modulator and cyclophilin ligand interactor and B-cell mature antigen. <i>Cellular Immunology</i> , 2015, 295, 127-136.	3.0	21
31	Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. <i>Cancer Letters</i> , 2013, 331, 220-229.	7.2	19
32	Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. <i>Human Immunology</i> , 2013, 74, 1111-1118.	2.4	19
33	Acute humoral rejection of kidney allografts in patients with a positive flow cytometry crossmatch (FCXM). <i>Clinical Transplantation</i> , 2000, 14, 15-20.	1.6	18
34	Significance of C4d deposition in antibody-mediated rejection. <i>Clinical Transplantation</i> , 2012, 26, 43-48.	1.6	18
35	Relation between human decay-accelerating factor (hDAF) expression in pig cells and inhibition of human serum anti-pig cytotoxicity: value of highly expressed hDAF for xenotransplantation. <i>Xenotransplantation</i> , 2007, 14, 67-73.	2.8	17
36	Reduction of α -galactosyl xenoantigen by expression of endo- α -galactosidase C in pig endothelial cells. <i>Xenotransplantation</i> , 2002, 9, 290-296.	2.8	16

#	ARTICLE	IF	CITATIONS
37	Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation. <i>Nephrology</i> , 2016, 21, 4-8.	1.6	16
38	In vivo gene transfer of endo-beta-galactosidase C removes alphaGal antigen on erythrocytes and endothelial cells of the organs. <i>Xenotransplantation</i> , 2004, 11, 444-451.	2.8	15
39	Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection. <i>Transplant International</i> , 2005, 18, 401-407.	1.6	14
40	Enzymatic removal of Î±Gal antigen in pig kidneys by ex vivo and in vivo administration of endo-Î²-galactosidase C. <i>Xenotransplantation</i> , 2002, 9, 228-236.	2.8	13
41	AMP-activated protein kinase as a promoting factor, but complement and thrombin as limiting factors for acquisition of cytoprotection: implications for induction of accommodation. <i>Transplant International</i> , 2013, 26, 1138-1148.	1.6	13
42	Impact of Arterial Reconstruction With Recipient's Own Internal Iliac Artery for Multiple Graft Arteries on Living Donor Kidney Transplantation. <i>Medicine (United States)</i> , 2015, 94, e1811.	1.0	13
43	5Â-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment. <i>International Immunopharmacology</i> , 2016, 39, 192-198.	3.8	13
44	How to estimate kidney function in kidney transplant recipients with mild to moderate kidney impairment: comparison of estimated glomerular filtration (eGFR) values between creatinine-based GFR equations and cystatin C-based GFR equations for Japanese population. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 130-134.	1.6	12
45	Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. <i>Transplant Immunology</i> , 2017, 40, 22-30.	1.2	12
46	A Single Perioperative Injection of Dexamethasone Decreases Nausea, Vomiting, and Pain after Laparoscopic Donor Nephrectomy. <i>Journal of Transplantation</i> , 2017, 2017, 1-8.	0.5	12
47	Enhancement of Tumor Proliferation by Cyclosporine A in Early Phase of Experimental Hepatic Metastasis. <i>Japanese Journal of Cancer Research</i> , 1994, 85, 704-709.	1.7	11
48	Immunosuppressive drugs and their effect on experimental tumor growth. <i>Transplant International</i> , 1995, 8, 251-255.	1.6	11
49	Prevention of free-radical induced apoptosis by induction of human recombinant Cu, Zn-SOD in pig endothelial cells. <i>Transplant International</i> , 2002, 15, 220-225.	1.6	11
50	1,25â€dihydroxyvitamin D synthesis after renal transplantation: the role of fibroblast growth factor 23 and cyclosporine. <i>Clinical Transplantation</i> , 2009, 23, 368-374.	1.6	11
51	Stimulation Index for PCNA mRNA in Peripheral Blood as Immune Function Monitoring After Renal Transplantation. <i>Transplantation</i> , 2009, 87, 1411-1414.	1.0	11
52	Functional Difference Between Membrane-bound and Soluble Human Thrombomodulin. <i>Transplantation</i> , 2015, 99, 702-709.	1.0	11
53	Evaluation of Interleukin-2 mRNA in Whole Blood as a Parameter for Monitoring Cyclosporine Pharmacodynamics. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 604-608.	1.4	10
54	Increased CD40L+PD-1+ follicular helper T cells (Tfh) as a biomarker for predicting calcineurin inhibitor sensitivity against Tfh-mediated B-cell activation/antibody production after kidney transplantation. <i>International Immunology</i> , 2018, 30, 345-355.	4.0	10

#	ARTICLE	IF	CITATIONS
55	Lower incidence of de novo donor-specific antibodies against HLA-DR in ABO-incompatible renal transplantation. <i>Human Immunology</i> , 2019, 80, 169-175.	2.4	10
56	Alternative Strategy for Overcoming ABO Incompatibility. <i>Transplantation</i> , 2007, 83, 1284-1286.	1.0	9
57	Virus-Associated Hemophagocytic Syndrome in Renal Transplant Recipients: Report of 2 Cases from a Single Center. <i>Case Reports in Hematology</i> , 2015, 2015, 1-4.	0.4	9
58	Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation. <i>Transplantation Proceedings</i> , 2019, 51, 1378-1381.	0.6	9
59	Clinical relevance of post-transplant pharmacodynamic analysis of cyclosporine in renal transplantation. <i>International Immunopharmacology</i> , 2014, 22, 384-391.	3.8	8
60	Inferior long-term graft survival after end-to-side reconstruction for two renal arteries in living donor renal transplantation. <i>PLoS ONE</i> , 2018, 13, e0199629.	2.5	8
61	Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFN γ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 371-375.	2.0	7
62	Surgical Techniques and Procedures for Kidney Transplant Recipients With Severe Atherosclerosis. <i>Experimental and Clinical Transplantation</i> , 2017, 15, 594-601.	0.5	7
63	The effectiveness and safety of computed tomographic peritoneography and video-assisted thoracic surgery for hydrothorax in peritoneal dialysis patients: A retrospective cohort study in Japan. <i>PLoS ONE</i> , 2020, 15, e0238602.	2.5	6
64	Interferon γ -induced HLA Class II expression on endothelial cells is decreased by inhibition of mTOR and HMGCoA reductase. <i>FEBS Open Bio</i> , 2020, 10, 927-936.	2.3	6
65	Enzyme-Linked Immunosorbent Assay for Human Leukocyte Antigen Antibody Detection and Urine Protein Test Recommended for Follow-Up Monitoring After Renal Transplantation. <i>Transplantation</i> , 2008, 85, 1595-1600.	1.0	5
66	Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 319-324.	1.6	5
67	Current activity of xenotransplantation in Japan. <i>Xenotransplantation</i> , 2019, 26, e12487.	2.8	5
68	A high molecular weight protein in axoplasm underlying excitable membrane of squid giant axon. <i>Biomedical Research</i> , 1983, 4, 615-618.	0.9	5
69	Liberation of vasoactive substances and its prevention with thromboxane A ₂ synthase inhibitor in pig liver transplantation. <i>Transplant International</i> , 1996, 9, 76-81.	1.6	4
70	Measurement of portal venous flow velocity with an implantable miniature Doppler probe in pig liver transplantation. <i>Transplant International</i> , 1997, 10, 116-120.	1.6	4
71	Changes in ABCB1 mRNA Expression in Peripheral Blood Cells before and after Renal Transplantation. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 1085-1090.	1.4	4
72	Peripheral blood immune response-related gene analysis for evaluating the potential risk of chronic antibody-mediated rejection. <i>Human Immunology</i> , 2018, 79, 432-438.	2.4	3

#	ARTICLE	IF	CITATIONS
73	Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study. <i>International Immunopharmacology</i> , 2021, 91, 107038.	3.8	3
74	Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. <i>Transplant International</i> , 2007, 20, 365-370.	1.6	2
75	Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 317-324.	1.6	1
76	Improved detection of donor-specific HLA-class II antibody in kidney transplant recipients by modified immunocomplex capture fluorescence analysis. <i>Transplant Immunology</i> , 2021, 67, 101418.	1.2	0
77	Two-year outcomes of low-exposure extended-release tacrolimus and mycophenolate mofetil regimen in <i>de novo</i> kidney transplantation: A multi-center randomized controlled trial. <i>Clinical Transplantation</i> , 2022, , e14655.	1.6	0